Clinician's Roundtable

Host: Raj Chovatiya, MD, PhD Here to share a glimpse into where the dermatology field might be headed based on updates from the Maui Derm 2025 conference is Dr. Raj Chovatiya. Dr. Chovatiya is a Clinical Associate Professor at the Rosalind Franklin University Chicago Medical School and Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago.

Host: Raj Chovatiya, MD, PhD Here to share his insights on the key themes and topics covered at the Maui Derm 2025 conference is Dr. Raj Chovatiya. Dr. Chovatiya is a Clinical Associate Professor at the Rosalind Franklin University Chicago Medical School and Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago.

Host: Raj Chovatiya, MD, PhD In light of the Maui Derm 2025 conference, Dr. Raj Chovatiya is here to discuss the most significant updates in the dermatology field that helped define 2024. Dr. Chovatiya is a Clinical Associate Professor at the Rosalind Franklin University Chicago Medical School and Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago.

Host: Raj Chovatiya, MD, PhD How should we approach caring for undifferentiated eczema patients who didn’t have eczema as a child, who doesn’t have atopic co-morbidities, and isn’t flexural? Here to give a quick overview of his session at the Maui Derm 2025 conference that sought to help answer this question is Dr. Raj Chovatiya. Dr. Chovatiya is a Clinical Associate Professor at the Rosalind Franklin University Chicago Medical School and Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago.

Guest: Rasheed A. Gbadegesin, MD, MBBS A new study by the H3 Africa Kidney Research Network found that APOL1 variants are a major risk factor for chronic kidney disease. Additionally, these variants are particularly prevalent among West Africans. Dr. Rasheed Gbadegesin dives into these findings and explains how they could contribute to preventive measures and improved outcomes in patients of African ancestry. Dr. Gbadegesin is the Director of the Office of Physician-Scientist Development at Duke University School of Medicine.

Guest: Mohamed Ibrahim, MB, BCh IgA nephropathy (IgAN) is a rare autoimmune kidney disease in which IgA deposits damage kidney filters, causing symptoms like proteinuria and swelling. While symptoms can overlap with other kidney diseases, IgAN presents challenges of its own. Learn about the unique characteristics of IgAN with Dr. Mohamed Ibrahim, an Assistant Professor of Transplant Nephrology at the University of Maryland School of Medicine.

Guest: Jennifer Moore, MS, RDN, CSR, LDN Host: Charles Turck, PharmD, BCPS, BCCCP IgA nephropathy, or IgAN, is a rare kidney disease that requires dietary changes to maintain kidney health and function while supporting other organ systems. Learn about the most crucial dietary considerations for these patients from Jennifer Moore, a renal nutrition expert.

Host: Gates B. Colbert, MD Guest: Kelly Helm Over 35 million people in the United States suffer from some form of chronic kidney disease, but many of them lack the support and education to navigate their condition and receive the best possible care. After her daughter was diagnosed with a rare kidney disease, Kelly Helm discovered the many obstacles associated with management and treatment. Hear from Kelly as she sits down with Dr. Gates Colbert to share what she’s learned as a parent, caregiver, and advocate. Kelly is the Executive Director of Patient Engagement at NephCure, a nonprofit organization dedicated to supporting and empowering patients with rare kidney diseases.

Host: Gerald Watts, MD, PhD There is a high unmet need for patients with persistent chylomicronemia. Plozasiran (ARO-APOC3) is an investigational drug that is being evaluated for these patients. Professor Gerald Watts shares the outcomes of the PALISADE trial, in which the efficacy and safety of plozasiran was examined in patients with familial chylomicronemia syndrome.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Amy McMichael, MD A recent study that looked at psoriasis in patients from different races and backgrounds found that there weren’t a significant number of differences in the factors studied between patients with skin of color and Caucasian patients. The one thing that was really quite impactful for patients who are Black is that they wanted to see more physicians who could speak to their cultural and ethnic backgrounds. So to learn more about the findings and how we can address these barriers, join Dr. Charles Turck as he dives in with Dr. Amy McMichael, Professor in the Department of Dermatology at Wake Forest School of Medicine in Winston-Salem, North Carolina.